Takeda and Hutchmed Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

OSAKA, Japan, CAMBRIDGE, Massachusetts, HONG KONG, SHANGHAI&, FLORHAM PARK, New Jersey, Friday May 26, 2023– Takeda (TSE:4502/NYSE:TAK) and HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (“HUTCHMED”) today announced that...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news